Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in